IRVINE, CA--(Marketwire - July 28, 2010) - AtheroNova Inc. (OTCBB: AHRO) AtheroNova Inc. (“AtheroNova”) announced that in compliance with all FINRA requirements its trading symbol returned to AHRO.OB as of the opening of the market yesterday, July 27, 2010. AtheroNova common stock began trading under the symbol (AHROD.OB) on June 26, 2010 after completion of a 1-for-200 reverse stock split as the final step in the Company’s corporate actions initiated with the merger with Z&Z Medical Holdings, Inc. (“Z&Z”) on May 13, 2010. “We are excited about the future prospects of the Company’s product development and think that the current stock price is a reflection of investors’ enthusiasm for our research in atherosclerosis therapy,” stated Thomas W. Gardner, the Company’s Chief Executive Officer. “Investors should continue to follow AtheroNova as we continue our research in interventional regression of plaque deposits,” he stated. “We invite those interested in our Company to visit our website at www.atheronova.com to follow our progress, check out our new logo and bookmark the site for future visits,” he concluded.
About AtheroNova Inc. and AtheroNova Operations, Inc.
AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The company is currently developing protocols for its second animal study at the Cedars-Sinai Division of Cardiology in conjunction with a major university to validate the findings of its initial study and prepare for human trials. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.
Prior to May 13, 2010, AtheroNova was a public “shell” company with nominal assets whose sole business was to identify, evaluate and investigate various companies to acquire or with which to merge.
Additional information about the merger, capital raise transaction and AtheroNova Operations, Inc. (formerly Z&Z Medical Holdings, Inc.), can be found in AtheroNova’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2010.
Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding completion of AtheroNova’s restructuring, commencement of the second animal trial and the development of applications for AtheroNova’s compounds. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova’s filings with the United States Securities and Exchange Commission. AhteroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Thomas Gardner
Chief Executive Officer
Or
Mark Selawski
Chief Financial Officer
(949) 476-1100
